Turning Point Therapeutics is a clinical-stage biopharmaceutical company designing and developing therapies that target genetic drivers of cancer. Co.'s main drug candidate, repotrectinib, is being evaluated for the treatment of patients with ROS1+ advanced non-small-cell lung cancer and patients with NTRK+ advanced solid tumors. Elzovantinib, Co.'s MET/SRC/CSF1R inhibitor, is being evaluated in its ongoing Phase 1 SHIELD-1 clinical trial, in patients with advanced solid tumors harboring genetic alterations in MET. Co.'s clinical trial of its RET inhibitor, TPX-0046 in patients with advanced solid tumors is ongoing. Co.'s fourth drug candidate, TPX-0131, is an ALK inhibitor. We show 16 historical shares outstanding datapoints in our TPTX shares outstanding history coverage, used to compute TPTX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing TPTX market cap history over the course of time is important for investors
interested in comparing TPTX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of TPTX versus a peer is one thing; comparing
TPTX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like TPTX can fluctuate over the course of history.
With this page we aim to empower investors researching TPTX by allowing them to research the TPTX market cap history. |
Free TPTX Email Alerts:
Video: The Importance of Market Cap
